Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months–5 Years — United States, June 2022
Updated US Guidelines for Using Moderna and Pfizer COVID-19 Vaccines in Children 6 Months to 5 Years Old (June 2022)
AI simplified
Abstract
On June 17, 2022, the FDA issued Emergency Use Authorization for the Moderna and Pfizer-BioNTech COVID-19 vaccines for children aged 6 months to 5 years.
- The Moderna vaccine is administered as 2 doses of 25 µg each, 4 weeks apart for children aged 6 months-5 years.
- The Pfizer-BioNTech vaccine is given as 3 doses of 3 µg each, with specific intervals of 3 weeks between the first two doses and at least 8 weeks between the second and third doses for children aged 6 months-4 years.
- Both vaccines met the criteria for immunobridging, showing comparable neutralizing antibody levels in young children to those in young adults.
- Efficacy analyses were conducted during the predominance of the Omicron variant of SARS-CoV-2.
- No specific safety concerns were identified for either vaccine among recipients.
AI simplified